vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and OLB GROUP, INC. (OLB). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.8M, roughly 1.4× OLB GROUP, INC.). OLB GROUP, INC. runs the higher net margin — -83.7% vs -265.2%, a 181.5% gap on every dollar of revenue. Over the past eight quarters, OLB GROUP, INC.'s revenue compounded faster (-28.7% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
OLB Group, Inc. is a global financial technology provider offering omnichannel payment processing solutions, e-commerce enablement tools, and digital banking services for small and medium-sized enterprises across North America, Europe, and key Asia-Pacific markets. Its core segments include merchant services, crypto payment integration, and cloud-based business management platforms.
BOLT vs OLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $1.8M |
| Net Profit | $-6.6M | $-1.5M |
| Gross Margin | — | — |
| Operating Margin | -283.4% | -83.7% |
| Net Margin | -265.2% | -83.7% |
| Revenue YoY | — | -35.2% |
| Net Profit YoY | 58.4% | 67.5% |
| EPS (diluted) | $-9.38 | $-0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $1.8M | ||
| Q3 25 | $2.2M | $2.3M | ||
| Q2 25 | $1.8M | $2.3M | ||
| Q1 25 | $1.2M | $2.3M | ||
| Q4 24 | $0 | $2.7M | ||
| Q3 24 | $1.1M | $3.1M | ||
| Q2 24 | $1.3M | $3.5M | ||
| Q1 24 | $5.3M | $3.5M |
| Q4 25 | $-6.6M | $-1.5M | ||
| Q3 25 | $-7.1M | $-1.2M | ||
| Q2 25 | $-8.6M | $-2.1M | ||
| Q1 25 | $-11.0M | $-1.1M | ||
| Q4 24 | $-15.9M | $-4.6M | ||
| Q3 24 | $-15.2M | $-1.6M | ||
| Q2 24 | $-21.2M | $-2.6M | ||
| Q1 24 | $-10.8M | $-2.4M |
| Q4 25 | -283.4% | -83.7% | ||
| Q3 25 | -355.1% | -49.1% | ||
| Q2 25 | -510.5% | -74.8% | ||
| Q1 25 | -991.4% | -36.6% | ||
| Q4 24 | — | -166.0% | ||
| Q3 24 | -1441.1% | -52.9% | ||
| Q2 24 | -1772.3% | -74.3% | ||
| Q1 24 | -324.1% | -82.6% |
| Q4 25 | -265.2% | -83.7% | ||
| Q3 25 | -329.4% | -50.8% | ||
| Q2 25 | -474.6% | -93.7% | ||
| Q1 25 | -903.4% | -46.9% | ||
| Q4 24 | — | -167.1% | ||
| Q3 24 | -1330.1% | -52.9% | ||
| Q2 24 | -1662.4% | -75.2% | ||
| Q1 24 | -205.0% | -67.8% |
| Q4 25 | $-9.38 | $-0.48 | ||
| Q3 25 | $-3.72 | $-0.13 | ||
| Q2 25 | $-4.46 | $-0.66 | ||
| Q1 25 | $-0.29 | $-0.47 | ||
| Q4 24 | $-13.73 | $-3.55 | ||
| Q3 24 | $-7.93 | $-0.92 | ||
| Q2 24 | $-11.12 | $-1.49 | ||
| Q1 24 | $-0.28 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $4.6M |
| Total Assets | $56.7M | $12.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | — | ||
| Q3 25 | $31.9M | — | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $38.8M | $29.3K | ||
| Q4 24 | $47.3M | $27.4K | ||
| Q3 24 | $53.8M | $41.3K | ||
| Q2 24 | $73.7M | $53.3K | ||
| Q1 24 | $91.3M | $3.3K |
| Q4 25 | $26.5M | $4.6M | ||
| Q3 25 | $32.1M | $5.3M | ||
| Q2 25 | $38.8M | $6.4M | ||
| Q1 25 | $46.8M | $2.3M | ||
| Q4 24 | $57.2M | $3.2M | ||
| Q3 24 | $72.0M | $6.7M | ||
| Q2 24 | $85.9M | $8.3M | ||
| Q1 24 | $104.2M | $11.0M |
| Q4 25 | $56.7M | $12.3M | ||
| Q3 25 | $65.1M | $12.2M | ||
| Q2 25 | $75.5M | $12.4M | ||
| Q1 25 | $85.9M | $12.5M | ||
| Q4 24 | $99.6M | $12.7M | ||
| Q3 24 | $109.3M | $15.9M | ||
| Q2 24 | $124.2M | $16.6M | ||
| Q1 24 | $142.9M | $18.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-1.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-1.3M | ||
| Q3 25 | $-9.7M | $-115.5K | ||
| Q2 25 | $-9.6M | $-1.0M | ||
| Q1 25 | $-13.4M | $-155.8K | ||
| Q4 24 | $-14.4M | $-2.6M | ||
| Q3 24 | $-14.0M | $-376.7K | ||
| Q2 24 | $-16.1M | $-785.5K | ||
| Q1 24 | $-16.8M | $-424.7K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOLT
Segment breakdown not available.
OLB
| Transaction And Processing Fees | $1.7M | 94% |
| Other | $99.2K | 6% |
